1. Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2Agonist Therapy: Part 2
- Author
-
Roger L. Waite, Thomas J H Chen, Siobhan Morse, Eric Stice, John Giordano, Eric R Braverman, Mallory Kerner, Andrew Smolen, Joel F. Lubar, Amanda Lih Chaun Chen, Frank Fornari, Kenneth Blum, Margaret A. Madigan, Cameron Allen, B. William Downs, and James E. Thompson
- Subjects
Agonist ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.drug_class ,General Medicine ,Electroencephalography ,Placebo ,Crossover study ,law.invention ,Endocrinology ,Randomized controlled trial ,law ,Dopamine ,Internal medicine ,Medicine ,Allele ,Beta wave ,business ,Psychiatry ,medicine.drug - Abstract
Background: It is well established that in both food- and drug-addicted individuals there is “dopamine resistance” associated with the DRD2 gene A1 allele. Based on earlier studies, evidence is emerging wherein the potential of utilizing a natural, nonaddicting, safe, putative D2 agonist may play a significant role in the recovery of individuals with reward deficiency syndrome, including those addicted to psychoactive chemicals. Findings: Positive outcomes demonstrated by quantitative electroencephalographic (qEEG) imaging in a randomized, triple-blind, placebo-controlled, crossover study involving oral Synaptose Complex KB220Z™ showed an increase of alpha waves and low beta wave activity in the parietal brain region. Using t statistics, significant differences observed between placebo and Synaptose Complex KB220Z™ consistently occurred in the frontal regions after week 1 and then again after week 2 of analyses (P = 0.03). This is the first report to demonstrate involvement of the prefrontal corte...
- Published
- 2010
- Full Text
- View/download PDF